Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Immatics stock logo
IMTX
Immatics
$5.44
+5.8%
$4.52
$3.30
$13.77
$661.23M0.87648,285 shs446,357 shs
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
$2.30
+15.6%
$2.10
$1.61
$11.20
$147.26M0.93779,582 shs2.34 million shs
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
$2.85
-0.7%
$4.04
$2.28
$6.71
$361.53M1.851.18 million shs814,703 shs
Valneva SE stock logo
VALN
Valneva
$6.40
+0.5%
$6.58
$3.62
$9.50
$535.27M1.8542,313 shs2,217 shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Immatics stock logo
IMTX
Immatics
+5.84%+4.62%+11.70%+24.20%-52.90%
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
+15.58%+19.17%-3.77%-24.09%-67.47%
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
-0.70%-4.04%-41.60%-54.19%+10.89%
Valneva SE stock logo
VALN
Valneva
+0.47%+1.11%-0.78%-5.19%-28.01%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Immatics stock logo
IMTX
Immatics
2.1126 of 5 stars
3.62.00.00.02.81.70.0
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
1.8772 of 5 stars
3.61.00.00.03.11.70.0
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
4.0945 of 5 stars
3.31.00.04.33.33.30.6
Valneva SE stock logo
VALN
Valneva
2.2634 of 5 stars
3.55.00.00.01.50.80.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Immatics stock logo
IMTX
Immatics
3.20
Buy$14.67169.61% Upside
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
3.10
Buy$20.43788.20% Upside
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
2.50
Moderate Buy$5.5092.98% Upside
Valneva SE stock logo
VALN
Valneva
3.00
Buy$15.50142.19% Upside

Current Analyst Ratings Breakdown

Latest LRMR, ORGO, VALN, and IMTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/28/2025
Immatics stock logo
IMTX
Immatics
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$10.00
5/8/2025
Valneva SE stock logo
VALN
Valneva
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$15.00 ➝ $14.00
4/15/2025
Valneva SE stock logo
VALN
Valneva
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$17.00 ➝ $17.00
4/9/2025
Valneva SE stock logo
VALN
Valneva
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$17.00 ➝ $17.00
4/1/2025
Immatics stock logo
IMTX
Immatics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight
3/31/2025
Valneva SE stock logo
VALN
Valneva
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$17.00 ➝ $17.00
3/25/2025
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
3/25/2025
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$26.00 ➝ $26.00
3/25/2025
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$15.00 ➝ $16.00
3/25/2025
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$13.00 ➝ $10.00
3/24/2025
Valneva SE stock logo
VALN
Valneva
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$17.00 ➝ $15.00
(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Immatics stock logo
IMTX
Immatics
$144.15M4.59N/AN/A$2.88 per share1.89
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
N/AN/AN/AN/A$1.86 per shareN/A
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
$458.76M0.79$0.18 per share15.72$2.11 per share1.35
Valneva SE stock logo
VALN
Valneva
$186.06M2.88N/AN/A$2.00 per share3.20
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Immatics stock logo
IMTX
Immatics
-$104.98M-$0.17N/AN/AN/A-47.94%-15.90%-9.38%8/12/2025 (Estimated)
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
-$36.95M-$1.49N/AN/AN/AN/A-35.87%-32.37%8/6/2025 (Estimated)
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
$4.95M-$0.17N/AN/AN/A-1.62%-2.69%-1.63%8/14/2025 (Estimated)
Valneva SE stock logo
VALN
Valneva
-$109.78M-$1.19N/AN/AN/A-4.35%-3.93%-1.42%8/12/2025 (Estimated)

Latest LRMR, ORGO, VALN, and IMTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Immatics stock logo
IMTX
Immatics
-$0.39-$0.35+$0.04-$0.35$14.92 million$20.12 million
5/8/2025Q1 2025
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
$0.04-$0.13-$0.17-$0.17$90.77 million$86.69 million
5/7/2025Q1 2025
Valneva SE stock logo
VALN
Valneva
-$0.40-$0.13+$0.27-$0.13$41.80 million$51.79 million
4/30/2025Q1 2025
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
-$0.42-$0.46-$0.04-$0.46N/AN/A
3/27/2025Q4 2024
Immatics stock logo
IMTX
Immatics
-$0.03$0.48+$0.51$0.48$16.16 million$15.67 million
3/24/2025Q4 2024
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
-$0.29-$0.45-$0.16-$0.45N/AN/A
3/20/2025Q4 2024
Valneva SE stock logo
VALN
Valneva
-$0.22-$0.54-$0.32-$0.54$55.64 million$56.48 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Immatics stock logo
IMTX
Immatics
N/AN/AN/AN/AN/A
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
N/AN/AN/AN/AN/A
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
N/AN/AN/AN/AN/A
Valneva SE stock logo
VALN
Valneva
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Immatics stock logo
IMTX
Immatics
N/A
3.98
3.98
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
N/A
13.10
13.10
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
0.21
3.09
2.74
Valneva SE stock logo
VALN
Valneva
0.70
2.78
2.25

Institutional Ownership

CompanyInstitutional Ownership
Immatics stock logo
IMTX
Immatics
64.41%
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
91.92%
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
49.57%
Valneva SE stock logo
VALN
Valneva
11.39%

Insider Ownership

CompanyInsider Ownership
Immatics stock logo
IMTX
Immatics
3.30%
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
4.50%
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
33.00%
Valneva SE stock logo
VALN
Valneva
14.91%
CompanyEmployeesShares OutstandingFree FloatOptionable
Immatics stock logo
IMTX
Immatics
260121.55 million115.42 millionOptionable
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
3064.03 million61.57 millionOptionable
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
950126.85 million79.33 millionOptionable
Valneva SE stock logo
VALN
Valneva
70083.64 million69.15 millionNot Optionable

Recent News About These Companies

US Advises Older Travelers to Avoid Chikungunya Vaccine
FDA follows EMA in limiting use of Valneva shot

New MarketBeat Followers Over Time

Media Sentiment Over Time

Immatics stock logo

Immatics NASDAQ:IMTX

$5.44 +0.30 (+5.84%)
Closing price 05/29/2025 04:00 PM Eastern
Extended Trading
$5.38 -0.06 (-1.18%)
As of 05/29/2025 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

Larimar Therapeutics stock logo

Larimar Therapeutics NASDAQ:LRMR

$2.30 +0.31 (+15.58%)
Closing price 05/29/2025 04:00 PM Eastern
Extended Trading
$2.32 +0.02 (+0.87%)
As of 05/29/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.

Organogenesis stock logo

Organogenesis NASDAQ:ORGO

$2.85 -0.02 (-0.70%)
Closing price 05/29/2025 04:00 PM Eastern
Extended Trading
$2.95 +0.10 (+3.51%)
As of 05/29/2025 07:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.

Valneva stock logo

Valneva NASDAQ:VALN

$6.42 +0.05 (+0.86%)
As of 05/29/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.